RecruitingPhase 2NCT05750628

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Patients With Uncomplicated Plasmodium Falciparum Malaria

Sponsor

Novartis Pharmaceuticals

Enrollment

327 participants

Start Date

Jan 23, 2024

Study Type

INTERVENTIONAL

Conditions

Uncomplicated Plasmodium falciparum malaria

Summary

Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria

Eligibility

Min Age: 2 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INE963, a drug called KAE609 (Cipargamin), and others for people with uncomplicated plasmodium falciparum malaria. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 2 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINE963

oral INE963

DRUGKAE609 (Cipargamin)

oral KAE609 (Cipargamin)

DRUGSoC (Coartem)

SoC (Coartem)

DRUGKLU156

oral sachet KLU156 (KAF156 + lumefantrine)

Locations(12)

Novartis Investigative Site

Banfora, Burkina Faso

Novartis Investigative Site

Nanoro, Burkina Faso

Novartis Investigative Site

Abidjan, Côte d’Ivoire

Novartis Investigative Site

Azaguié, Côte d’Ivoire

Novartis Investigative Site

Lambaréné, Gabon

Novartis Investigative Site

Libreville, Gabon

Novartis Investigative Site

Kintampo, Ghana

Novartis Investigative Site

Navrango, Ghana

Novartis Investigative Site

Ahero, Kisumu County, Kenya

Novartis Investigative Site

Kisumu, Kenya

Novartis Investigative Site

Kampala, Uganda

Novartis Investigative Site

Tororo, Uganda

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05750628

Related Trials

A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines

NCT059515951 location